Targeted delivery, maximized bioavailability, minimal invasiveness, minimal side effects and cost–effectiveness are all markers of a successful drug delivery method. Although topical therapy, where diseased skin is targeted, remains a method of limited use, transdermal drug delivery systems seek to utilize skin as a vehicle for deeper systemic effects. Recently, Tadros et al. outlined an innovation to maximize the potential of topical delivery as a minimally invasive, user-friendly and safe medium. STAR particles seek to improve transdermal delivery by creating micropores in the stratum corneum. Several investigations have been conducted with promising results, including in vitro and in vivo animal and human studies. Despite a number of limitations and further considerations, the potential implications of STAR particles in the clinical disease setting are monumental.